Background {#Sec1}
==========

Antimicrobial "allergy labels" describing Adverse Drug Reactions (ADRs) are frequently reported. Traditionally, antimicrobials have been known to elicit both Type A ADRs (non-immune mediated) and Type B ADRs (immune mediated), the later typically avoided due to fear of phenotypic recurrence \[[@CR1], [@CR2]\]. However the prevalence and impact of antimicrobial Type A and B ADRs is not well defined. Despite the varied pathogenesis of antimicrobial ADRs, the approach to antimicrobial allergy labeling is often the same \[[@CR3], [@CR4]\]. The impact antimicrobial ADRs have on antimicrobial stewardship, prescribing, infectious diseases practice and restricted antimicrobial usage is relatively unknown \[[@CR5]\]. Utilizing an Australian National Antimicrobial Prescribing Survey (NAPS) prospective database we estimate the prevalence of antimicrobial "allergy labels" and ADRs in an Australian inpatient tertiary hospital population receiving antimicrobial therapy. We describe the commonly implicated antimicrobials in ADRs and allergy descriptions. Furthermore, we assess the impact of antimicrobial "allergy labels" and ADRs on antimicrobial appropriateness and restricted antimicrobial usage.

Methods {#Sec2}
=======

The study was performed at The Alfred hospital, a 350-bed tertiary referral center. Two prevalence surveys were conducted over a 1 week period in November 2013 and 2014 as part of the prospective National Antimicrobial Prescribing Survey (NAPS) \[[@CR6]\]. The NAPS was developed in 2011 to assess Australian health care facility antimicrobial prescribing practices. The NAPS identifies inpatients receiving antimicrobial therapy during the prevalence periods, prospectively recording patient antimicrobial usage (agent, dose, frequency, route, duration) and baseline demographics (age, sex, admitting unit, allergy history), infection history (infective diagnosis) and antimicrobial appropriateness score. The NAPs captures recorded patient antimicrobial "allergies" and ADRs from medical records and/or drug charts.

After NAPS data collection patients were assigned to one of two groups based upon the presence of a recorded antimicrobial "allergy label" or ADR: (i) Antimicrobial Allergy/ADR (AA) or (ii) No Antimicrobial Allergy/ADR (NAA). Study investigators JAT and JAE independently defined patient AA description(s) as per published definitions as either likely (i) Type A, (ii) Type B (Class I -- IV), or (iii) Unspecified (U) \[[@CR7]\].. When consensus could not be reached a third study investigator was recruited for a tie-breaking vote. Antimicrobial usage and antimicrobial appropriateness were compared between AA and NAA groups.

An infectious diseases physician defined antimicrobial appropriateness according to NAPS criteria: 1 (optimal), 2 (adequate), 3 (suboptimal), 4 (inadequate) or 5 (not assessable) \[[@CR6]\]. A score of one or two was considered to be 'appropriate' and three or four as 'inappropriate'.

A Type A ADR was defined as a non-immune mediated reaction that relates to the predictable pharmacological properties of a drug. A Type B ADR was defined as an immune mediated reaction that does not related to the predictable pharmacological properties of a drug \[[@CR1]\]. This was subcategorized into one of four classes: (i) Immediate (IgE), (ii) accelerated or delayed (Cytotoxic IgG), (iii) accelerated or delayed (Immune complex IgG) and (iv) Delayed (T cell-mediated) \[[@CR2], [@CR7]\]. The duration of antibiotic therapy was the number of days from the recorded commencement of antibiotic therapy until the date of the survey. For this study, restricted broad-spectrum antibiotic was defined as a carbapenem, fluoroquinolone or glycopeptide antibiotic. 'De-labeling' is defined as the removal or revision of an antibiotic allergy label following clinical allergy assessment and/or allergy testing or re-challenge \[[@CR5]\]. Alfred Health Human Research Ethics Committee approval was obtained for NAPS data collection.

Statistical analysis {#Sec3}
--------------------

Categorical variables were summarized using frequency and percentage and compared between groups using a chi-square test. Continuous variables were summarized using mean and standard deviation (SD) or median and inter-quartile range as appropriate and compared using a paired t-test or Wilcoxon signed-rank test as appropriate. A univariate negative binomial regression model was utilized, a variant of a poisson regression allowing for over-dispersion, to test the null hypothesis of no difference in cumulative days of antimicrobial exposure between groups. Standard errors were estimated using the robust Huber White sandwich estimator.

Results {#Sec4}
=======

We identified 509 patients according to NAPS inclusion criteria from the combined point prevalence periods, 245 from 2013 and 264 from 2014. The baseline cohort demographics are outlined in Table [1](#Tab1){ref-type="table"}. Twenty-five percent (128/509) of patients identified in the NAPs database had a documented report of "antimicrobial allergy" or ADR (AA). The prevalence of "allergy labels"/ADR was 10 % (51/509) for penicillin V/G, 5 % (24/509) cephalosporins, 4 % (22/509) trimethroprim-sulfamethoxazole/sulphonamide antibiotics and 3 % (17/509) aminopenicillins. The distribution of patients between admitting units was similar in the AA and NAA groups (*p* = 0.58), however a higher male predominance in the NAA versus AA group was noted (66 % vs. 49 %, *p* = 0.007).Table 1Baseline demographics for NAPS cohort (2013-2014)Cohort demographicsAANAATotal*N* = 128*N* = 381*N* = 509Age (years) Median585959Sex Male63 (49)252 (66)315 (61)Admitting Unit Specialist medical73 (57)160 (42)233 (46) General medical23 (18)40 (11)63 (12) General surgical6 (5)31 (8)37 (7) Specialty surgical25 (2)147 (39)172 (34) Other^a^1 (1)3 (1)4 (1)Immunosuppressed^b^ Yes33 (26)76 (20)109 (21)Total drug allergies128 (100)5 (1)133 (26)Total antimicrobials administered2977731070Route of antimicrobial administration (*n* = 1070) Oral177(60)356 (46)533 (50) Intravenous102 (34)371 (48)473 (44) Other^c^18 (6)46 (6)64 (6)^a^Emergency (3), Intensive care unit (1)^b^Haematology, oncology, lung and heart transplant units^c^Inhaled, topical

Antimicrobial allergy descriptions {#Sec5}
----------------------------------

In the 128 patients reporting one or more allergies/ADRs, there were 202 antimicrobial allergies and ADRs recorded in the allergy record for the 128 patients. Of these 202 antimicrobials, 102 (50 %) were considered likely Type B, 48 (24 %) Type A, 51 (25 %) unspecified and 1 % anaphylactoid (2/202). Of those Type B ADRs, 39 % (40/102) had clinical findings consistent with Class I (immediate) reactions and 61 % (62/102) Class IV (delayed). Fifty-four percent (109/202) of reported antimicrobial ADRs were toward a β-lactam, 62 % (67/109) Type B, 17 % (19/109) Type A and 21 % (23/109) unspecified. The complete list of antimicrobial allergies and reported ADRs are demonstrated in Table [2](#Tab2){ref-type="table"}.Table 2Reported antimicrobial allergies and ADRs for the AA cohortReported Antimicrobial Allergy or ADRTotal*N* = 202 (%)*Beta*-*lactams*109 (54)Penicillin^a^54Amoxicillin/Ampicillin12Amoxicillin-clavulanate5Flucloxacillin3Ticarcillin-clavulanate5Piperacillin-tazobactam4Cephalosporins (not specified)3Cephalexin/Cephazolin14Cefuroxime2Ceftriaxone1Ceftazadime3Cefepime1Meropenem2*Non*-*beta lactams*93 (46)Vancomycin7Clindamycin/lincamycin6Trimethoprim-sulfamethoxazole21Dapsone5Clarithromycin2Doxycycline2Erythromycin11Roxithromycin4Metronidazole2Tobramycin4Aminoglycosides (NS)1Norfloxacin1Ciprofloxacin7Moxifloxacin3Antiretroviral therapy5Azoles^b^6Other^c^6^a^Penicillin -- Penicillin V, Penicillin G. ^b^Ketoconazole, fluconazole, voriconazole^c^Quinine (1), Linezolid (1), Amphoterician (1), clotrimazole (1), Rifampacin (1), terbinafine (1)

Antimicrobial usage and appropriateness {#Sec6}
---------------------------------------

From the 509 patients, 1070 antimicrobials were prescribed during the study periods, 297 for the AA group versus 773 for the NAA group. The top five antimicrobial agents administered for the AA and NAA groups are displayed in Table [3](#Tab3){ref-type="table"}. The median antimicrobial duration was longer in the AA versus NAA group (6 days vs. 4 days; *p* = 0.018), whilst there was a non-significant increase in the proportion with inappropriate antimicrobial prescribing in the AA group compared with NAA (29 %; 35/120 vs. 23 %; 86/367, *p* = 0.22). Oral antimicrobial administration was higher in the NAA than AA group (60 %; 177/297 vs. 46 %; 356/793, *p* = 0.0001). The proportion of patients that received a β-lactam or cephalosporin was lower in the AA versus NAA groups, 60 % vs. 79 % (*p* = 0.0001) and 24 % vs. 43 % (*p* = 0.05) respectively. There was no difference in the proportion of AA versus NAA patients that received a restricted antimicrobial, 25 % vs. 24 % (*p* = 0.44). Sixty three percent (56/89) of patients reported to be allergic to at least one β-lactam still received a β-lactam antibiotic.Table 3The most frequent antimicrobials used (in order) for patients with and without antimicrobial "allergy labels" (AA vs. NAA)AA group(*n* = 278)1Ciprofloxacin 15 (5 %)2Cephazolin 13 (5 %)3Ceftazadime 12 (4 %)4Ceftriaxone 11 (4 %)5Meropenem 10 (4 %)NAA group(*n* = 792)1Cephazolin 69 (9 %)2Ceftriaxone 59 (7 %)3Piperacillin-tazobactam 47 (6 %)4Ciprofloxacin 40 (5 %)5Amoxicillin -- clavulanate 33 (4 %)

It was estimated that the AA compared to NAA patients had a non-statistically significant 38 % increase in antimicrobial days exposure (R 0.328, 95 % CI-0.72--0.72, *p* = 0.11) and 31 % increase in antibiotic days exposure (R 0.27, 95 % CI:-0.14--0.68, *p* = 0.19).

Discussion {#Sec7}
==========

By utilizing single center data from the NAPS survey, we were able to demonstrate a high prevalence of total antimicrobial "allergy labels" and ADRs (25 %) in our mixed inpatient population receiving antimicrobial therapy, 55 % of which were consistent with a non-immediate reaction. Our findings are broadly consistent with other reported international studies, but with some interesting differences. We found a quarter of patients had been labeled as having an "allergy" which is at the higher end of previously reported studies \[[@CR5], [@CR8], [@CR9]\]. Charneski et al. demonstrated in a large group of general medical and surgical patients that 11 % had an antimicrobial "allergy label" \[[@CR3]\]. Lee et al. revealed 25 % antibiotic allergy prevalence, however with a higher rate of immediate reactions than illustrated in our cohort (32 % vs. 20 %) \[[@CR10]\].

Identifying patients with either known drug side effects (Type A) or non-severe delayed reactions (Type B) may potentially allow for supervised re-challenge to aid appropriate antimicrobial therapy \[[@CR11]\]. However, recent reports suggest this definition may require re-evaluation, as Type A reactions may in fact be dose dependent and genetically predisposed, whilst Type B in some cases non-immune mediated (e.g. non-IgE mediated mast cell activation by fluoroquinolones) \[[@CR1], [@CR12], [@CR13]\]. Nonetheless, we identified that 54 % of our study population have likely non-immediate ADRs, highlighting a potential for direct re-challenge and "de-labeling" in those unlikely to be genetically predisposed \[[@CR14]\]. β-lactams are often the preferred therapy in many invasive infections, yet often avoided due to a distant history of non-immediate allergy or Type A ADR. The lower uptake of β-lactams in our NAA group may be potentially addressed in the future by direct re-challenge or formal SPT/IDT programs\[[@CR14]\]. Clinical programs that have utilized antibiotic re-challenge in 'low risk' phenotypes, predominately 'unknown' or Type A ADRs, have demonstrated an increase in β-lactam usage post implementation \[[@CR15]\]. Interestingly, 60 % of our patients with a β-lactam "allergy" received a β-lactam; the resultant proportion that was subsequently "de-labeled" is unclear. The importance of "de-labeling" strategies is strengthened by studies that have highlighted that an antibiotic "allergy label" is associated with increased costs, antibiotic exposure and resistant organism generation \[[@CR4], [@CR5], [@CR16]\].

This study is limited by small study numbers, recall bias of true ADR descriptions by patients and assessment of prescribing over short study periods. Whilst clarification of which patients had "mislabeled" AA would be preferred, the fact that most clinicians are known to act upon these labels without clarification is significant \[[@CR17]\]. The study does highlight the need for both a better understanding, as well as a management strategy to assess patients with antimicrobial allergy/ADR "labels". Although the study had limited power to determine differences in prescribing practices, ciprofloxacin was the most frequently used antimicrobial in the AA group and meropenem was represented in the "top 5", albeit with no appreciable difference in restricted antimicrobial usage between the groups. Inappropriate prescriptions were more frequently identified in AA patients, and although not statistically significant, this 'signal' requires further evaluation in larger cohorts. Furthermore, the AA group had an increased exposure to antimicrobials (i.e. duration), which we intend to also explore more fully in a larger dataset.

Conclusion {#Sec8}
==========

We identified an antimicrobial "allergy label" prevalence of 25 % in our tertiary referral center, 10 % for a penicillin "allergy label". The majority of adverse drug reactions recorded were against β-lactams (50 %), with a predominance of non-immediate ADRs. The high rate of β-lactam use in patients with a β-lactam "label" raises questions about the validity of these ADRs and/or presence of a selective side chain allergy. A higher amount of intravenous antimicrobial administration and trend toward increased inappropriate antimicrobial prescription in the AA group was also noted. Further assessment of the entire NAPS database, paying particular attention to the highest users of antimicrobial therapy (i.e. immunosuppressed) may further clarify if the differences seen in antimicrobial exposure are significant.

ADR

:   Adverse drug reactions

AA

:   Antimicrobial allergy

NAA

:   No antimicrobial allergy

Type A ADR

:   An adverse drug reaction that is secondary to a known drug side effect and not immune mediated

Type B ADR

:   An adverse drug reaction that is secondary to an immune mediated mechanism
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